Browse Companies

Ranpak Holdings Corp. reported revenue growth of 7.1% in 2025 to $395 million, despite operating losses widening to $24.3 million and net losses of $38.3 million. The company’s core business leverages a razor/razor-blade model with recurring high-margin consumable paper products tied exclusively to its proprietary protective packaging systems. Automation solutions contributed 10% of revenue, reflecting strategic investments in machine vision and robotics partnerships. Geographic diversification spans North America (47%), Europe (45%), and Asia (8%), supported by an expanding production footprint including a new Malaysia facility. Operating cash flow remained positive at $23.1 million, though free cash flow was negative due to substantial capital expenditures exceeding $55 million. Key risks include supplier concentration for kraft paper, customer concentration among large e-commerce end-users, supply chain disruptions, and evolving regulatory requirements on sustainable packaging. Growth drivers focus on global e-commerce expansion, sustainable cold chain solutions, and continued product innovation.

NRC Health reported a record total recurring contract value of approximately $152 million as of early 2026, highlighting strength in its core healthcare analytics subscription model. However, ongoing client attrition and liquidity constraints reflected in key ratios underscore operational risks that could hamper growth sustainability. Executive leadership alignment through significant stock grants further signals a focus on stabilizing performance. The company operates in a competitive healthcare insights market where durable moats are challenged by pricing pressures and churn. Close monitoring of contract renewals and liquidity improvements will be critical going forward.

Evaxion A/S, a clinical-stage biotechnology company utilizing its AI-Immunology™ platform, achieved significant revenue growth in 2025 driven by licensing and collaborative agreements with Merck & Co. The company reduced its operating loss compared to the prior year amid steady R&D spending focused on advancing its vaccine pipeline. Capital structure improvements through equity issuance and debt conversion enhanced liquidity, providing a runway into late 2027. While losses continue reflecting reinvestment typical of the clinical stage, operational progress and financial resilience position Evaxion for upcoming milestones tied to clinical development and partnerships.

Liquidia Corp has developed a proprietary inhaled formulation of treprostinil, YUTREPIA, approved by the FDA in May 2025 and currently driving commercial revenues alongside a generic treprostinil injection marketed with Sandoz. The company’s financials show substantial operating losses but improving trends as commercialization progresses. Future growth depends on manufacturing capacity expansions, ongoing clinical development of liposomal formulations, and navigating pricing and regulatory challenges amid cost-containment pressures. Despite improved cash flow from operations, net losses persist, underscoring the importance of capital management and operational execution over the near term.

Linear Minerals Corp, a junior resource company focused on lithium exploration in Quebec, has reduced its net loss significantly from FY2024 to FY2025 through lower exploration and administrative expenses. The Augustus Lithium Project remains the company's key asset, supported by ongoing drilling programs and a joint venture with Infini Resources. Despite cost discipline, liquidity is constrained with working capital declining sharply, necessitating continued equity financing. Growth depends on exploration success and securing additional funds amid typical risks for early-stage resource companies.

flyExclusive, an emerging player in the fractional aviation ownership sector, has demonstrated improving operating and net income trends from 2022 through 2025 despite substantial losses and negative equity. Its operational momentum is powered by a specialized fractional ownership program and a strategic merger with Jet.AI. However, persistent legal disputes with Wheels Up Partners LLC present sizable risks to liquidity and management focus. The firm’s capital structure relies heavily on secured debt with recent amendments extending maturities but maintaining high interest rates, coinciding with limited short-term liquidity metrics. Going forward, watch for legal resolutions, liquidity events, and integration milestones to gauge sustainability of growth.

MYERS INDUSTRIES INC demonstrated a sharp rebound in net income for fiscal 2025, with profitability surging over 385% year-over-year while revenue declined roughly 12.6%. Key drivers included operational efficiency gains, cost controls, and contribution from the Signature Systems acquisition in its composite matting products segment. The company manages leverage actively via interest rate swaps amidst significant long-term debt and maintains a solid current ratio of 1.67. Shareholder returns remain stable through sustained dividends, though buybacks are modest relative to historical levels. Looking ahead, uncertainty around segment variability and strategic reviews including the tire supply business pose risks to margin sustainability.

Rand Capital Corp's financial trajectory shifted markedly between fiscal years 2024 and 2025, moving from a net loss of approximately $2.95 million to a net income exceeding $1 million. This rebound reflects strategic portfolio management focused on preferred stock, term notes, and warrants with negotiated terms supporting income stability. Despite slower operating cash flow year-over-year, dividend distributions expanded considerably, with flexible options for shareholders. Ongoing risks tied to credit exposure and bankrupt holdings underscore the fragility of returns, while liquidity remains solid at over $4 million in cash and equivalents. Market watchers should monitor portfolio valuations and dividend policies as the company balances risk with capital return priorities.

Acorn Energy, through its OmniMetrix subsidiary, has stabilized profitability by leveraging proprietary IoT solutions despite a challenging revenue history. The 2025 introduction of the Omni product family and RADex module marks a strategic phase enhancing connectivity and operational efficiency for critical energy infrastructure monitoring. While customer concentration and competitive pressures persist, improved operating cash flow and technology leadership via the OCOM platform suggest a foundation for measured growth and margin improvement.

In Q1 2026, CorMedix Inc. continues to leverage its FDA-approved DefenCath antimicrobial catheter lock solution amid ongoing clinical trials for expanded patient indications while integrating its recent Melinta Therapeutics acquisition that broadens its commercial portfolio with six marketed anti-infectives. The company maintains a strong current ratio near 3.0, supporting operational scalability despite inherent risks linked to reimbursement dynamics, manufacturing dependencies, and patent litigation challenges. CorMedix’s growth is anchored on penetrating hospital and outpatient dialysis settings through multi-year supply agreements covering a majority of U.S. outpatient dialysis centers, with potential upside from new indications and synergies from the expanded infectious disease product lines.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in liver and viral disease drug candidates, reported a net loss of $24.2 million in 2025, significantly improved from $131.2 million in 2024. Operating income remained negative at approximately -$88 million, reflecting sustained R&D investments. The company held $77.8 million in cash, cash equivalents, and short-term investments at year-end 2025, providing runway into Q3 2026. Ongoing capital raises and collaborations are critical to continue operations amid increasing clinical development expenses. Growth prospects depend on successful clinical outcomes, regulatory milestones, and strategic partnerships.

Climb Bio, a clinical-stage biotech, focuses on potentially best-in-class monoclonal antibodies for immune-mediated diseases, primarily through its lead candidate budoprutug targeting CD19-positive B cells. The company improved operating losses from $82 million in 2024 to $67.9 million in 2025, supported by over $160 million in cash and equivalents expected to fund operations into 2028. Budoprutug’s Phase 2 pMN trial and Phase 1b/2a ITP and SLE studies, alongside early trials of CLYM116 in IgAN, form key growth catalysts but remain subject to typical biotech clinical and regulatory risks. Climb Bio navigates a competitive landscape with established pharma players while managing high R&D expenses and complex regulatory environments.

Distribution Solutions Group, Inc. (DSG) operates four specialized distribution segments serving fragmented industrial and electronics markets in North America. Between 2023 and 2025, DSG exhibited consistent top-line growth driven by acquisitions and organic gains, particularly from expanding its Canadian operations and TestEquity’s rental equipment business. However, margin erosion due to higher costs and sales mix shifts poses a challenge. The company refinanced debt in late 2025 to extend maturities but maintains substantial leverage with floating interest rates. Management’s increased stock repurchase authorization signals confidence despite modest net income and limited returns on equity.

Silence Therapeutics plc, a London-based biotech firm specializing in RNAi therapeutics, reported significant deterioration in operating and net income for 2025, with operating losses widening by nearly 44% year-over-year and net losses almost doubling. Despite a sharp revenue drop previously reported in mid-2025, the company maintains strong liquidity with a current ratio above 8, supporting its continued R&D investments. The recent transition to U.S. issuer status on Nasdaq marks a strategic move expected to enhance capital access amid ongoing cash burn. Cybersecurity risk management remains a key governance focus during this pivotal phase. Going forward, pipeline progress and capital preservation will be critical milestones to monitor.

In the first quarter of 2026, Bioventus Inc. initiated commercial launches of its recently FDA-cleared Peripheral Nerve Stimulation (PNS) devices, marking a pivotal step in expanding its non-opioid pain management portfolio. This product rollout, coupled with the benefits of a July 2025 credit agreement that refinanced legacy debt and extended maturities to 2030, enhances the company’s competitive positioning and financial flexibility. While the orthopedic medical device market remains competitive and subject to reimbursement complexities, Bioventus’s diversified product offering and strengthened balance sheet underpin its growth prospects.

MediWound Ltd. operates in the specialized burn and wound treatment sector with its flagship product Nexobrid, supported by robust government contracts and key partnerships. Despite a 16% revenue decline in 2025, the company has invested heavily in expanding manufacturing capacity via a new GMP-compliant facility and sustained growth in R&D expenses, particularly for its diabetic foot ulcer product EscharEx. Persistent net losses highlight operational challenges amid high execution costs, while government funding through BARDA and MTEC remains crucial. The company's liquidity profile shows a healthy current ratio with active equity raises backing its strategy, but customer concentration and regulatory uncertainties suggest ongoing risk factors.

Compass Therapeutics, a clinical-stage oncology-focused biopharma, leverages its proprietary bispecific StitchMabs™ platform to target angiogenesis and immune pathways. Its lead candidate, tovecimig, demonstrated significant efficacy in a Phase 2/3 biliary tract cancer trial with key survival data expected in April 2026. Despite promising clinical milestones, the company continues to incur substantial operating losses driven by R&D investments and negative cash flows, holding $30.6 million in cash at year-end 2025. The firm faces regulatory complexities and relies on third-party manufacturing as it seeks to advance commercialization prospects.

Kura Oncology, founded in 2014, progressed from R&D focus to a commercial-stage biopharma by late 2025 with FDA approval and U.S. launch of KOMZIFTI (ziftomenib), its menin inhibitor targeting relapsed/refractory AML patients with NPM1 mutations. The drug’s differentiated safety profile and market access underpin the company’s moat, supported by collaboration with Kyowa Kirin. Despite initial commercial revenues, Kura continues to report deep losses driven by significant commercialization and research investments, reflected in its worsening operating income and cash flow metrics for fiscal 2025. Its diversified pipeline beyond AML, including next-generation inhibitors targeting solid tumors and diabetes, provides future growth avenues yet uncertain due to clinical and regulatory risks.

HUTCHMED (China) Ltd has evolved from a mixed venture portfolio to focus intensively on oncology and immunology drug development. While consolidated revenue declined in recent years, net income surged in 2025 largely due to a significant gain on divestment of its equity stake in Shanghai Hutchison Pharmaceuticals. The company’s solid capital base supports continued investment in its pipeline, with research and development expenses moderating as it shifts toward earlier-stage assets. Future growth depends heavily on clinical progress, commercialization success of internal drugs like fruquintinib and tazemetostat, and partnerships with global pharmaceutical players. Regulatory complexities and the competitive landscape in China remain key risks.

CPI Card Group Inc. reported a 15.9% revenue increase in fiscal 2025 to $84.14 million, driven by sustained demand across its card products and personalization services [F1]. Despite top-line growth, operating income declined 12.7% to $54.8 million due to inflationary pressures and supply chain challenges, while net income fell 23.4% to $14.95 million [F1][S1][S8]. Operating cash flow rose 37.4% to $59.5 million, supporting significant capital investments including a near doubling of capex to $18.2 million focused on capacity expansion and technology upgrades [F1][S16]. The company maintains substantial leverage with over $308 million in long-term debt and negative equity impacting return metrics [F1][S4][S18]. Customer concentration remains high, with one customer representing approximately 16% of revenues and the top ten accounting for more than half [S5]. Strategic integration of Arroweye Solutions aims to enhance product offerings but poses near-term earnings headwinds [N3].

Tango Therapeutics has demonstrated revenue growth driven by collaborations, particularly with Gilead Sciences, and equity financing fueling its pipeline advancement. Despite significant operating losses, the company maintains a robust cash position that supports operations into 2028. Key assets include multiple precision oncology candidates in early clinical and IND-enabling stages, although regulatory and development risks remain high. Monitoring clinical milestones and capital expenditure will be critical to assessing upcoming inflection points.

Invivyd, Inc. reported a more than doubling of revenue in 2025 to $53.4 million driven by commercial sales of its authorized COVID-19 prophylactic monoclonal antibody, PEMGARDA. Despite this progress, the company incurred a net loss of $52.5 million and negative operating cash flow of $58.1 million due to continued investments in R&D and commercialization. Its next-generation candidate VYD2311 is advancing through Phase 3 trials, representing a future growth opportunity. However, substantial doubt remains regarding Invivyd's ability to continue as a going concern beyond one year without additional capital or achievement of revenue milestones tied to loan agreements. Investors should monitor regulatory updates, clinical progress, and capital raising efforts closely.

GH Research PLC operates at the forefront of psychedelic-inspired medicines targeting treatment-resistant depression, progressing its lead candidates GH001 and GH002 through IND status and Phase 3 preparation, supported by proprietary delivery technology. Financially, the company has ramped up R&D spending which has driven a year-over-year decline in net income by approximately 24%, yet maintained strong liquidity with cash and equivalents growing from $183 million to nearly $281 million over 2024–2025. The firm’s capital allocation focuses on drug development, IP protection, and preparing for potential commercialization with no dividend or buyback activity, reflecting its clinical-stage biotech status. Key risks include clinical trial outcomes, regulatory hurdles, foreign exchange volatility, and cybersecurity threats—all managed within an evolving corporate governance framework under Irish law.

Immatics N.V. focuses on developing immunotherapies targeting the intracellular cancer antigen PRAME, employing cutting-edge T-cell receptor technology to circumvent limitations of conventional therapies. The company's recent years have been marked by substantial growth in clinical-stage programs and strategic collaborations, supported by significant equity capital raises and a robust cash position as of year-end 2025. Despite posting a sizeable net loss in 2025, largely due to escalating R&D expenditures amid ongoing clinical activities, Immatics is preparing for potential commercial launches, backed by state-of-the-art manufacturing facilities and alliances with partners such as Moderna and Bristol Myers Squibb. The biopharma faces key risks from competitive advances, regulatory complexities, financing variability from collaboration revenues, and manufacturing dependencies; monitoring milestone achievements and regulatory progress will be critical indicators of future performance.

Ferrellgas Partners' most recent quarterly filings dated June 5, 2026, indicate a cautious maintenance of liquidity with a current ratio slightly above 1, underscoring tight financial operating conditions. Despite substantial net debt exceeding $1.38 billion as of April 30, 2026, the firm shows operational continuity, supported by its general partner structure and retail wholesale propane business model. Sector headwinds related to commodity price volatility and balance sheet leverage weigh on margin expansion prospects. Key near-term watch points include potential refinancing events and operational efficiency initiatives that could shape the company’s trajectory.

Shattuck Labs is developing first-in-class monoclonal antibodies targeting the DR3 receptor for inflammatory diseases, notably SL-325 for inflammatory bowel disease (IBD). The company’s proprietary approach aims to offer superior pathway blockade and immunogenicity profile compared to existing TL1A blockers. Financially, Shattuck Labs shows steady reduction in losses driven by clinical progress, supported by a solid cash runway extending into 2029. Phase 1 trials of SL-325 are underway with Phase 2 initiation planned in Crohn’s Disease patients by Q3 2026. Key risks include regulatory uncertainties, capital needs, and competitive pressures typical of early-stage biotech.

Hippo Holdings transformed from multi-year net losses into profitability in 2025 by scaling its premium base to $468.6 million while improving underwriting precision through proprietary technology. Its multi-carrier platform, including owned and partner MGAs supported by the Spinnaker capacity initiative, diversified product offerings beyond homeowners insurance. However, risks remain from severe weather volatility and a fragmented regulatory landscape that constrain growth and capital deployment. Future progress depends on navigating these headwinds while leveraging technology and expanding market reach.

Enhabit, Inc. reported stable operating conditions in its latest quarterly filing ahead of a merger slated to close in mid-2026. The company specializes in home health and hospice care, generating revenue primarily through Medicare and other insurance reimbursements, which impose regulatory complexity and pricing pressure. Its competitive position benefits from specialized capabilities and deep regulatory compliance experience but faces ongoing risks related to reimbursement changes and leveraged capital structure. Key near-term catalysts include shareholder approval of the $688 million acquisition by Kinderhook-backed Anchor Parent, with operational integration and financial performance in focus thereafter.

Following its emergence from Chapter 11 bankruptcy and relisting on the NYSE in mid-2024, LATAM Airlines Group posted robust operational and financial results in 2025. Passenger traffic surged to 87.4 million travelers, driven by capacity expansions especially in domestic Brazil and international routes. Cargo operations showed volume growth but faced yield pressures amid competitive trade corridors. Financially, the company managed liquidity tightly with extended credit facilities and disciplined debt refinancing, supporting increased dividends and fleet investments despite a current ratio below one. Going forward, LATAM’s performance hinges on managing rising personnel costs, fuel price volatility, currency fluctuations, and regulatory complexities across Latin America.

StubHub Holdings remains a leading player in the global secondary ticket marketplace, leveraging its technology and brand to connect buyers and sellers worldwide. However, FY2025 revealed steep operating losses nearing $1.34 billion and a widening net loss of over $1.9 billion, underscoring profitability challenges. The company's strategic pivot toward enabling content rights holders to issue tickets directly—original issuance—is an ambitious growth vector but faces considerable execution and adoption barriers. Additionally, intensifying competition, complex regulatory landscapes including securities litigation, and rising debt service obligations all weigh heavily on StubHub’s capacity to invest while managing liquidity.

Niagen Bioscience, Inc. (NAGE) has demonstrated strong top-line growth and profitability gains over recent years driven by its core nicotinamide riboside chloride (NRCL) technology. Its proprietary Niagen® ingredient supports both consumer and pharmaceutical applications, with notable expansion in finished products like Tru Niagen®. The company reported nearly $130 million revenue in 2025, a 30% increase from the prior year, alongside positive operating income of $16.3 million and net income of $17.4 million. Capital allocation has been conservative with modest buybacks and steady R&D investment focused on expanding the NAD+ precursor pipeline. Key risks include supplier concentration, competitive pressures, evolving regulations, and the challenge of sustaining growth amid market shifts. Near-term milestones to monitor include pharmaceutical segment development progress and international market expansion execution.

Keros Therapeutics is developing protein therapeutics targeting the TGF-β family, with lead candidates rinvatercept for neuromuscular diseases including Duchenne muscular dystrophy and ALS, and elritercept for hematologic cytopenias. The company achieved profitability in 2025 driven by licensing revenues from Takeda Pharmaceuticals and marked clinical progress including completion of a Phase 1 trial for rinvatercept and initiation of a Phase 3 trial for elritercept. Keros's strong cash position and collaboration agreements support upcoming clinical milestones in 2026, though risks remain around clinical development, regulatory approvals, and competitive pressures.

Costamare Inc. has maintained stable profitability despite a significant drop in revenue following the 2025 spin-off of its dry bulk business. The company owns a diversified fleet of 79 containerships underpinned by long-term, fixed-rate charters with major global liner firms, which provide revenue visibility and operational stability. Ongoing fleet expansion through newbuild vessels and sale-leaseback acquisitions alongside active capital management define Costamare’s medium-term growth outlook. Key risks include customer concentration and market cyclicality inherent in shipping.

Westwood Holdings Group Inc demonstrated robust operational performance in Q1 2026, delivering a 64% increase in income attributable to the company and a 13% rise in economic earnings year-over-year. The firm's fee-based, value-oriented investment advisory and trust services continue to underpin stable recurring revenue streams, despite volatility in the trust segment. Westwood invests in digital solutions to meet evolving client expectations but faces industry challenges from asset redemption risks, regulatory scrutiny, and integration of acquisitions. The company’s solid liquidity position and zero debt afford flexibility as it seeks to capitalize on growth opportunities.

Cracker Barrel Old Country Store, Inc. continues to leverage its distinctive integrated restaurant and retail format to navigate a challenging environment marked by input cost inflation and labor market tightness. The company recorded a 22% increase in operating income and a 13.3% rise in net income for FY2025, driven by menu innovation and guest experience enhancements. Rising commodity prices and wage inflation have pressured margins, prompting strategic initiatives focused on menu evolution and operational efficiency. Capital allocation balances dividends and share repurchases within debt covenant constraints while generating positive free cash flow supporting maintenance capital expenditures.

Innoviz Technologies Ltd. has pursued aggressive growth through pioneering LiDAR technologies incorporating sensor fusion, color cameras, and NVIDIA-powered edge computing platforms. However, its financial results reveal ongoing net losses exacerbated by significant revenue concentration, with over 80% of sales tied to one main customer. While liquidity remains robust with a current ratio near 3, profitability challenges and heavy customer dependency shape the company's risk profile. The firm’s future growth hinges on expanding product adoption beyond existing customers and navigating automotive OEM cycles, complemented by stringent cybersecurity governance overseen at the board level.